Nine-valent human papillomavirus vaccine: great science, but will it save lives?

The Lancet
Nov 11, 2017 Volume 390 Number 10108 p2121-2214
http://www.thelancet.com/journals/lancet/issue/current

Comment
Nine-valent human papillomavirus vaccine: great science, but will it save lives?
Lynette Denny
In The Lancet, Warner K Huh and colleagues1 report their final analysis of a randomised, double-blind trial of 14 215 women, aged 16–26 years, testing the quadrivalent human papillomavirus (qHPV; HPV types 6, 11, 16, and 18) vaccine compared with the nine-valent HPV (9vHPV; HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine. The women were recruited from 105 study sites located in 18 countries and received vaccination on day 1 and months 2 and 6. The 9vHPV vaccine consists of virus-like particles of HPV 6, 11, 16, and 18 (as found in the qHPV vaccine) and an additional five types, HPV 31, 33, 45, 52, and 58, combined with the adjuvant amorphous aluminium hydroxyphosphate sulphate.